At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 202 enrolled
Drug / intervention
MenACWY-CRM +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers
In Brief
A Phase 2 clinical trial evaluating MenACWY-CRM and MenACWY-TT for Meningococcal Disease. Completed, enrolled 202 participants across 4 sites.
Detailed Summary
Evaluate the immune response and reactogenicity of one dose of Meningococcal ACWY-cross reactive material (CRM) and Meningococcal ACWY-tetanus toxoid (TT) in 12-15 months old healthy toddlers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeningococcal Disease
CountriesItaly
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedNov 2013
Primary CompletionApr 2014
Study CompletionOct 2014
TodayJul 2026
First PostedNov 26, 2013
Enrollment StartNov 1, 2013
Primary CompletionApr 1, 2014
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 12.6 years ago
Interventions
MenACWY-CRMbiological
MenACWY-CRM
MenACWY-TTbiological
MenACWY-TT